Hematologic parameters of BERKAA and BERKSS mice treated with dabigatran (10 mg/g chow) or placebo
| Variable . | AA/Con . | AA/Dab . | SS/Con . | SS/Dab . |
|---|---|---|---|---|
| RBC (106/µL) | 8.9 ± 0.1 | 9.2 ± 0.3 | 6.0 ± 0.3*** | 6.2 ± 0.5*** |
| Hematocrit (%) | 37.0 ± 0.6 | 37.1 ± 1.1 | 27.7 ± 1.5*** | 28.5 ± 2.1*** |
| RDW (%) | 18.6 ± 0.5 | 18.1 ± 0.3 | 28.1 ± 0.8* | 27.9 ± 1.4* |
| WBC (103/µL) | 2.9 ± 0.4 | 3.5 ± 0.7 | 28.3 ± 5.5*** | 23.6 ± 4.4*** |
| Neutrophil (103/µL) | 0.8 ± 0.1 | 0.7 ± 0.1 | 2.75 ± 0.5*** | 2.3 ± 0.4** |
| Lymphocyte (103/µL) | 2.1 ± 0.2 | 2.7 ± 0.6 | 24.0 ± 4.9*** | 20.3 ± 3.9** |
| Monocyte (103/µL) | 0.1 ± 0.01 | 0.1 ± 0.04 | 1.4 ± 0.3*** | 1.0 ± 0.2* |
| Platelet (103/µL) | 564 ± 19 | 554 ± 17 | 568 ± 34 | 537 ± 43 |
| Variable . | AA/Con . | AA/Dab . | SS/Con . | SS/Dab . |
|---|---|---|---|---|
| RBC (106/µL) | 8.9 ± 0.1 | 9.2 ± 0.3 | 6.0 ± 0.3*** | 6.2 ± 0.5*** |
| Hematocrit (%) | 37.0 ± 0.6 | 37.1 ± 1.1 | 27.7 ± 1.5*** | 28.5 ± 2.1*** |
| RDW (%) | 18.6 ± 0.5 | 18.1 ± 0.3 | 28.1 ± 0.8* | 27.9 ± 1.4* |
| WBC (103/µL) | 2.9 ± 0.4 | 3.5 ± 0.7 | 28.3 ± 5.5*** | 23.6 ± 4.4*** |
| Neutrophil (103/µL) | 0.8 ± 0.1 | 0.7 ± 0.1 | 2.75 ± 0.5*** | 2.3 ± 0.4** |
| Lymphocyte (103/µL) | 2.1 ± 0.2 | 2.7 ± 0.6 | 24.0 ± 4.9*** | 20.3 ± 3.9** |
| Monocyte (103/µL) | 0.1 ± 0.01 | 0.1 ± 0.04 | 1.4 ± 0.3*** | 1.0 ± 0.2* |
| Platelet (103/µL) | 564 ± 19 | 554 ± 17 | 568 ± 34 | 537 ± 43 |
Asterisks indicate statistical significance compared with BERKAA mice within the same treatment (*P < .05, **P < .01, and ***P < .001). There were no statistically significant differences in any parameters between dabigatran and control within BERKAA or BERKSS mice.
Con, control placebo; Dab, dabigatran; RDW, red cell distribution width; WBC, white blood cell.